L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
Johanna HuttunenSoile PeltokangasMikko GyntherTeemu NatunenMikko HiltunenSeppo AuriolaMarika RuponenKati-Sisko VellonenKristiina M HuttunenPublished in: Scientific reports (2019)
L-Type Amino Acid Transporter 1 (LAT1/Lat1) is responsible for carrying large, neutral L-amino acids as well as several drugs and prodrugs across the blood-brain barrier (BBB). However, the BBB is not the only barrier that hinders drugs acting effectively within the brain; the brain parenchymal cell membranes represent a secondary barrier for the drugs with intracellular target sites. In this study, expression and function of Lat1 was quantified in mouse primary neuron, astrocyte and immortalized microglia (BV2) cultures. Moreover, ability of Lat1 to carry prodrugs inside these brain cells was evaluated. The results showed that Lat1 was localized at the similar level in all studied cells (3.07 ± 0.92-3.77 ± 0.91 fmol/µg protein). The transporter was also functional in all three cell types, astrocytes having the highest transport capacity and affinity for the LAT1/Lat1-substrate, [14C]-L-leucine, followed by neurons and microglia. The designed prodrugs (1-6) were able to utilize Lat1 for their cellular uptake and it was mainly much higher than the one of their parent drugs. Interestingly, improved cellular uptake was also achieved in cells representing Alzheimer's Disease phenotype. Therefore, improved delivery and intra-brain targeting of drugs can be attained by utilizing LAT1/Lat1 and prodrug approach.
Keyphrases
- amino acid
- induced apoptosis
- inflammatory response
- cell cycle arrest
- white matter
- resting state
- blood brain barrier
- stem cells
- cell therapy
- poor prognosis
- drug delivery
- cell proliferation
- cognitive decline
- cerebral ischemia
- brain injury
- signaling pathway
- multiple sclerosis
- lps induced
- solid state
- subarachnoid hemorrhage